Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotics for Paraneoplastic Thrombocythemia in Ovarian Cancer
ChiCTR2300067850Phase 4Not yet recruiting
- Sponsor
- Jingdezhen Second People's Hospital
- Start
- Feb 2023
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in ovarian cancer and thrombocytosis comparing Bifidobacterium longum with Placebo (2 arms). Primary endpoints: platelets and fecal microbiota composition. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
bifidobacterium longum
03
Conditions
ovarian cancerthrombocytosis
Beyond the preview
Go deeper on ChiCTR2300067850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067850.